Home › Compare › NBSE vs ADC

NBSE vs ADC: Dividend Comparison 2026

NBSE yields 529.10% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NBSE wins by $95355.78M in total portfolio value
10 years
NBSE
NBSE
● Live price
529.10%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95355.96M
Annual income
$69,511,989,565.27
Full NBSE calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — NBSE vs ADC

📍 NBSE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNBSEADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NBSE + ADC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NBSE pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBSE
Annual income on $10K today (after 15% tax)
$44,973.54/yr
After 10yr DRIP, annual income (after tax)
$59,085,191,130.48/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, NBSE beats the other by $59,085,122,452.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBSE + ADC for your $10,000?

NBSE: 50%ADC: 50%
100% ADC50/50100% NBSE
Portfolio after 10yr
$47678.07M
Annual income
$34,756,035,181.28/yr
Blended yield
72.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

NBSE
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
Altman Z
-10.6
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBSE buys
0
ADC buys
0
No recent congressional trades found for NBSE or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNBSEADC
Forward yield529.10% ✓4.13%
Annual dividend / share$2.00$3.10 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4% ✓
Portfolio after 10y$95355.96M ✓$178.9K
Annual income after 10y$69,511,989,565.27 ✓$80,797.29
Total dividends collected$93138.90M ✓$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: NBSE vs ADC ($10,000, DRIP)

YearNBSE PortfolioNBSE Income/yrADC PortfolioADC Income/yrGap
1← crossover$63,610$52,910.05$10,990$580.36+$52.6K → NBSE
2$382,606$314,543.11$12,301$860.26+$370.3K → NBSE
3$2,177,551$1,768,162.86$14,104$1,298.62+$2.16M → NBSE
4$11,734,902$9,404,922.59$16,691$2,008.16+$11.72M → NBSE
5$59,924,074$47,367,729.01$20,580$3,205.09+$59.90M → NBSE
6$290,177,156$226,058,396.40$26,754$5,330.02+$290.15M → NBSE
7$1,333,544,009$1,023,054,452.33$37,196$9,345.14+$1333.51M → NBSE
8$5,820,882,501$4,393,990,410.63$56,244$17,523.09+$5820.83M → NBSE
9$24,153,246,984$17,924,902,708.82$94,286$35,736.21+$24153.15M → NBSE
10$95,355,963,839$69,511,989,565.27$178,949$80,797.29+$95355.78M → NBSE

NBSE vs ADC: Complete Analysis 2026

NBSE — Stock

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Full NBSE Calculator →

ADC — REIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this NBSE vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBSE vs SCHDNBSE vs JEPINBSE vs ONBSE vs KONBSE vs MAINNBSE vs NNNNBSE vs EPRTNBSE vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.